Scholarlink

Purpose <p>To describe Undifferentiated Pleomorphic Sarcoma of Bone (UPSB) treated in Germany, Austria, or Switzerland and using the same treatment-approach as for osteosarcoma.</p> Patients and methods <p>The database of the Cooperative Osteosarcoma Study Group (COSS) was screened for UPSB. Eligible patients were evaluated for patient, tumor, and treatment related variables, and outcomes.</p> Results <p>One-hundred thirty-two eligible patients were identified (median age 41.7 (range: 10.3–74.6) years; males 58%; preceding malignancies 11%; tumor-sites extremities 86%, trunk 12%, head &amp; neck 2%). Relative tumor size was &lt; 1/3 of the involved bone in 83% of evaluable cases, pathologic fractures were present in 14% (limb-primaries only), and primary distant metastases in 6%. All patients received chemotherapy and 96% surgery for their primary (81% limb-salvage for extremity lesions). The response rate to preoperative chemotherapy was 38%. After a median follow-up of 3.9 (1&#xa0;day–34.1) years for event-free and 5.2 (0.2–34.1) years for overall survival, the 5&#xa0;year event-free and overall survival probabilities were 63% (standard error: 5%) and 70% (4%), respectively. Younger patient age, an extremity tumor, and localized disease predicted superior outcomes, pathologic fractures and limb-salvage surgery worse. The extent of tumor response to pre-operative chemotherapy seemed to have no impact on prognosis.</p> Discussion <p>UPSB generally affects considerably older persons than does the more frequent osteosarcoma. Despite a lower response rate to preoperative chemotherapy, its prognosis is at least comparable, if not better. Several prognostic factors impacting outcome could be defined. These results provide a benchmark for this rare disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Undifferentiated pleomorphic sarcoma of bone (UPSB) treated in the German-speaking countries. A report of 132 unselected patients from the Cooperative Osteosarcoma Study Group (COSS)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月20日

查看全文
  • Stefan S. Bielack,
  • Dimosthenis Andreou,
  • Daniel Baumhoer,
  • Claudia Blattmann,
  • Godehard Friedel,
  • Birgit Fröhlich,
  • Semi Ben Harrabi,
  • Leo Kager,
  • Thekla von Kalle,
  • Torsten Kessler,
  • Matthias Kevric,
  • Antonia Knoll,
  • Thomas Kühne,
  • Peter Reichardt,
  • Benjamin Sorg,
  • Reinhard Windhager,
  • Stefanie Hecker-Nolting

摘要

Purpose

To describe Undifferentiated Pleomorphic Sarcoma of Bone (UPSB) treated in Germany, Austria, or Switzerland and using the same treatment-approach as for osteosarcoma.

Patients and methods

The database of the Cooperative Osteosarcoma Study Group (COSS) was screened for UPSB. Eligible patients were evaluated for patient, tumor, and treatment related variables, and outcomes.

Results

One-hundred thirty-two eligible patients were identified (median age 41.7 (range: 10.3–74.6) years; males 58%; preceding malignancies 11%; tumor-sites extremities 86%, trunk 12%, head & neck 2%). Relative tumor size was < 1/3 of the involved bone in 83% of evaluable cases, pathologic fractures were present in 14% (limb-primaries only), and primary distant metastases in 6%. All patients received chemotherapy and 96% surgery for their primary (81% limb-salvage for extremity lesions). The response rate to preoperative chemotherapy was 38%. After a median follow-up of 3.9 (1 day–34.1) years for event-free and 5.2 (0.2–34.1) years for overall survival, the 5 year event-free and overall survival probabilities were 63% (standard error: 5%) and 70% (4%), respectively. Younger patient age, an extremity tumor, and localized disease predicted superior outcomes, pathologic fractures and limb-salvage surgery worse. The extent of tumor response to pre-operative chemotherapy seemed to have no impact on prognosis.

Discussion

UPSB generally affects considerably older persons than does the more frequent osteosarcoma. Despite a lower response rate to preoperative chemotherapy, its prognosis is at least comparable, if not better. Several prognostic factors impacting outcome could be defined. These results provide a benchmark for this rare disease.